%0 Journal Article
%A Schmutz, Maximilian
%A Zucknick, Manuela
%A Schlenk, Richard F
%A Mertens, Daniel
%A Benner, Axel
%A Weichenhan, Dieter
%A Mücke, Oliver
%A Döhner, Konstanze
%A Plass, Christoph
%A Bullinger, Lars
%A Claus, Rainer
%T Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen.
%J Clinical epigenetics
%V 15
%N 1
%@ 1868-7075
%C [Erscheinungsort nicht ermittelbar]
%I BioMed Central
%M DKFZ-2023-02175
%P 171
%D 2023
%Z #EA:B370#LA:B370#
%X Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis. Dysregulation of the epigenetic machinery is a significant contributor to disease development. Some AML patients benefit from treatment with hypomethylating agents (HMAs), but no predictive biomarkers for therapy response exist. Here, we investigated whether unbiased genome-wide assessment of pre-treatment DNA-methylation profiles in AML bone marrow blasts can help to identify patients who will achieve a remission after an azacytidine-containing induction regimen.A total of n = 155 patients with newly diagnosed AML treated in the AMLSG 12-09 trial were randomly assigned to a screening and a refinement and validation cohort. The cohorts were divided according to azacytidine-containing induction regimens and response status. Methylation status was assessed for 664,227 500-bp-regions using methyl-CpG immunoprecipitation-seq, resulting in 1755 differentially methylated regions (DMRs). Top regions were distilled and included genes such as WNT10A and GATA3. 80
%K AML (Other)
%K Azacytidine (Other)
%K DNA methylation patterns (Other)
%K DNA-methylation (Other)
%K Epigenetics (Other)
%K HMA-treatment (Other)
%K Predictive biomarker (Other)
%K Predictive signature (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37885041
%R 10.1186/s13148-023-01580-z
%U https://inrepo02.dkfz.de/record/285002